Functional analysis of PIK3CA gene mutations in human colorectal cancer
- PMID: 15930273
- DOI: 10.1158/0008-5472.CAN-04-4114
Functional analysis of PIK3CA gene mutations in human colorectal cancer
Abstract
Mutations in the PIK3CA gene, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K), have been reported in human cancers, including colorectal cancer. Most of the mutations cluster at hotspots within the helical and kinase domains. Whereas H1047R, one of the hotspot mutants, is reported to have elevated lipid kinase activity, the functional consequences of other mutations have not been examined. In this study, we examined the effects of colon cancer-associated PIK3CA mutations on the lipid kinase activity in vitro, activation of the downstream targets Akt and p70S6K in vivo and NIH 3T3-transforming ability. Of eight mutations examined, all showed increased lipid kinase activity compared with wild-type p110alpha. All the mutants strongly activated Akt and p70S6K compared with wild-type p110alpha as determined by immunoblotting using phospho-specific antibodies. These mutants also induced morphologic changes, loss of contact inhibition, and anchorage-independent growth of NIH 3T3 cells. The hotspot mutations examined in this study, E542K, E545K, and H1047R, all had high enzymatic and transforming activities. These results show that almost all the colon cancer-associated PIK3CA mutations are functionally active so that they are likely to be involved in carcinogenesis.
Similar articles
-
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.Oncogene. 2013 Feb 7;32(6):768-76. doi: 10.1038/onc.2012.87. Epub 2012 Mar 19. Oncogene. 2013. PMID: 22430209
-
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.Mol Carcinog. 2005 May;43(1):59-63. doi: 10.1002/mc.20102. Mol Carcinog. 2005. PMID: 15791648
-
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.Cancer Res. 2003 Dec 1;63(23):8132-7. Cancer Res. 2003. PMID: 14678966
-
Genetic deregulation of the PIK3CA oncogene in oral cancer.Cancer Lett. 2013 Sep 28;338(2):193-203. doi: 10.1016/j.canlet.2013.04.005. Epub 2013 Apr 15. Cancer Lett. 2013. PMID: 23597702 Review.
-
Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.FEBS J. 2013 Jun;280(12):2758-65. doi: 10.1111/febs.12175. Epub 2013 Mar 1. FEBS J. 2013. PMID: 23384338 Review.
Cited by
-
Miniaturized protein profiling permits targeted signaling pathway analysis in individual circulating tumor cells to improve personalized treatment.J Transl Med. 2024 Sep 20;22(1):848. doi: 10.1186/s12967-024-05616-7. J Transl Med. 2024. PMID: 39304879 Free PMC article.
-
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.Acta Oncol. 2015 Apr;54(4):487-92. doi: 10.3109/0284186X.2014.990158. Epub 2014 Dec 31. Acta Oncol. 2015. PMID: 25549537 Free PMC article.
-
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Gut. 2013 Apr;62(4):540-9. doi: 10.1136/gutjnl-2012-302423. Epub 2012 Jul 14. Gut. 2013. PMID: 22798500 Free PMC article.
-
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation.Cancer Res. 2012 Jul 1;72(13):3260-9. doi: 10.1158/0008-5472.CAN-11-4141. Epub 2012 May 2. Cancer Res. 2012. PMID: 22552288 Free PMC article.
-
Phosphoinositide signalling in cancer: beyond PI3K and PTEN.Nat Rev Cancer. 2010 May;10(5):342-52. doi: 10.1038/nrc2842. Nat Rev Cancer. 2010. PMID: 20414202 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous